A Clinical Study of Legend Biotech BCMA-chimeric Antigen Receptor Technology in Treating Relapsed/Refractory (R/R) Multiple Myeloma Patients
Phase of Trial: Phase I/II
Latest Information Update: 03 Dec 2018
At a glance
- Drugs LCAR-B38M CAR-T cell therapy (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man; Proof of concept
- Acronyms LEGEND-2
- Sponsors Nanjing Legend Biotech
- 03 Dec 2018 Results (n=57) published in a Janssen media release.
- 03 Dec 2018 According to a Janssen media release, data were presented at the 60th American Society of Hematology (ASH) Annual Meeting.
- 23 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 31 Dec 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History